GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

For more control, third-party tools like TranslucentTB and TaskbarTools let users make the taskbar fully transparent or adjust its transparency level. These apps are easy to use, lightweight, and ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work of a team ...

GSK is also seeking damages to compensate for the alleged infringement as well as a “compulsory ongoing licensing fee” for the claimed technologies. “Moderna has reaped billions of dollars in revenue ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

To learn more about how states are preparing to conduct safe, secure, and transparent elections this November, the Ash Center hosted a webinar this month where participants could learn more straight ...

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...